Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.108 (
TAT
)
2,389
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Diagnostic validity of the
TAT
and a new picture projective test, the
PPT
, were compared for normal, depressed, and psychotic subjects. Generally, the
PPT
elicited more positive emotional tone, more activity, and fewer thematic deviations than the
TAT
. The
PPT
and
TAT
were essentially equal in the capacity to discriminate between stories of normal and depressed subjects; however, the
PPT
was superior in differentiating psychotics from normals and depressives. On the
PPT
, depressives told stories with gloomier emotional tone and psychotics made more perceptual distortions, thematic and interpretive deviations. None of these differences were apparent on the
TAT
. The
PPT
pictures seem to have more diagnostic validity than the
TAT
stimuli.
...
PMID:Comparing diagnostic validity of the TAT and a new picture projective test. 390 Mar 31
Gene therapy combined with chemotherapy to achieve synergistic therapeutic effects has been a hot topic in recent years. In this project, the human tumor necrosis factor-related apoptosis-inducing ligand-encoding plasmid gene (
TRAIL
) and doxorubicin (Dox)-coloaded multi-functional nanocarrier was constructed based on the theory of circulation, accumulation, internalization, and release. Briefly, polyethyleneimine (PEI) was selected as skeleton material to synthesize PEI-polyethylene glycol (PEG)-
TAT
(
PPT
). Dox was conjugated to PEI using C6-succinimidyl 6-hydrazinonicotinate acetone hydrazone (C6-SANH), and a pH-sensitive Dox-PEI (DP) conjugate was obtained. Then, intracellular cationic pH-sensitive cellular assistant
PPT
and DP were mixed to condense
TRAIL
, and
TRAIL
-Dox coloaded
PPT
/DP/
TRAIL
(PDT) nanocarriers were obtained by one-step assembly.
TRAIL
was completely condensed by DP or
PPT
when mass ratios (DP/
PPT
to
TRAIL
) were up to 100:64, which indicated that DP and
PPT
could be mixed at any ratio for
TRAIL
condensation. The intracellular uptake rate of PDT was enhanced (
P
<0.05) when the contents of
PPT
in PPT+DP increased from 0 to 30%. Free Dox and
TRAIL
-loaded nanocarriers (
PPT
/C6-SANH-PEI/
TRAIL
[PCT]) were selected as controls to verify the synergistic antitumor effects of PDT. Compared with free
TRAIL
, TRAIL-protein expression was upregulated by PDT and PCT on Western blotting assays. The in vitro cytotoxicity of PDT was significantly enhanced compared to free Dox and PCT (
P
<0.01). Furthermore, murine PDT nanocarriers showed higher in vivo antitumor ability than both the Dox group (
P
<0.05) and the murine PCT group (
P
<0.05). These results indicated that the
TRAIL
+ Dox synergistic antitumor effect could be achieved by PDT, which paves the way to gene-drug combination therapy for cancer.
...
PMID:Multifunctionalized polyethyleneimine-based nanocarriers for gene and chemotherapeutic drug combination therapy through one-step assembly strategy. 2926 63